DICE Therapeutics (NASDAQ:DICE) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of DICE Therapeutics (NASDAQ:DICE) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports.

According to Zacks, “DICE Therapeutics Inc. is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif. “

Other equities analysts have also issued research reports about the company. SVB Leerink assumed coverage on DICE Therapeutics in a report on Monday, October 11th. They set an outperform rating and a $46.00 price target on the stock. Bank of America assumed coverage on DICE Therapeutics in a report on Monday, October 11th. They issued a buy rating and a $41.00 price objective on the stock. Finally, Evercore ISI assumed coverage on DICE Therapeutics in a report on Monday, October 11th. They issued an outperform rating and a $60.00 price objective on the stock.

NASDAQ DICE opened at $16.86 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 26.79 and a current ratio of 26.79. DICE Therapeutics has a 52-week low of $16.06 and a 52-week high of $40.50. The business’s 50-day moving average is $27.12.

DICE Therapeutics (NASDAQ:DICE) last released its quarterly earnings results on Friday, November 12th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($1.77). Analysts predict that DICE Therapeutics will post -2.9 earnings per share for the current fiscal year.

Several institutional investors have recently modified their holdings of DICE. M&T Bank Corp purchased a new stake in DICE Therapeutics in the 3rd quarter worth approximately $256,000. Asymmetry Capital Management L.P. purchased a new stake in DICE Therapeutics in the 3rd quarter worth approximately $9,012,000. Sands Capital Ventures LLC purchased a new stake in DICE Therapeutics in the 3rd quarter worth approximately $103,129,000. TD Asset Management Inc. purchased a new stake in DICE Therapeutics in the 3rd quarter worth approximately $1,337,000. Finally, Citigroup Inc. purchased a new stake in DICE Therapeutics in the 3rd quarter worth approximately $43,000. Hedge funds and other institutional investors own 80.60% of the company’s stock.

DICE Therapeutics Company Profile

DICE Therapeutics Inc is a biopharmaceutical company. Its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics Inc is based in SOUTH SAN FRANCISCO, Calif.

See Also: Why Invest in Dividend Kings

Get a free copy of the Zacks research report on DICE Therapeutics (DICE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.